A minority of ILC overexpress the human epidermal growth factor receptor 2 (HER2), which is mainly attributed to the pleomorphic subtype [5], and this overexpression was associated with a worse prognosis in breast cancer [2,6], until the advent of anti-HER2 therapies. Here, ERBB2 is linked to breast carcinoma.